One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
about
Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutidePharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target RangesEfficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program.Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center.IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetesBenefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.Pursuit of a perfect insulin.Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes.Insulin degludec + liraglutide: a complementary combination.Basal Insulin Use With GLP-1 Receptor Agonists.Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysisA Plethora of GLP-1 Agonists: Decisions About What to Use and When.Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized cUse and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review.Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?Insulin Degludec/Liraglutide.
P2860
Q26751359-372830DE-CAE9-470B-90A8-DCB5C9333937Q30249371-40222D4B-7BB8-4DA2-ABD8-8661F4C305B0Q33588613-2CB4B0E9-9E3F-4564-984C-18C5B7CDCCEEQ33732598-6AD11F9A-D1E1-481D-9914-3AC13B0324ECQ33834266-5CF1701B-F406-47ED-8BDF-210120D25757Q36285880-FF5CE6DB-6CCD-44EE-BCCC-7D0A0BBF8D1AQ36360100-CC594394-3DDB-424A-AC2B-D73AD16A3723Q36712701-FD58478C-58D1-4120-B3B5-126A4AF913A0Q36971833-6D93BB07-FFC8-4B2D-9BDD-FC4A8FB5C721Q37337304-6AAFBD17-FF7A-4382-861B-0885FD1C5924Q37639300-D5B245A8-35D9-42A8-8AA1-38B1528B6176Q38622754-8250EF21-F1BD-4B1C-B96D-19541F86A1EDQ38629197-5666D1FE-D0F3-4B4D-B419-57374F087BDBQ38778988-FADE6838-49E2-46AB-8DFD-9E23F2087805Q38824034-2232A49D-8B9E-4BE2-84C1-5AEB088A77E6Q38833204-2BAFFFC4-E9AE-454C-A846-8A29FAB4B044Q38841043-D79E1B6A-B452-47BB-B3CA-DF69CBFDD2F2Q38911124-CCAF59D0-F3D9-4A0B-B00C-BC58C8585440Q38916256-0FEB2323-CAB7-4B48-A0CB-B32BAB481AB3Q38940711-578399B2-F5E8-4E71-ACC7-8C6F8DECC10FQ38975192-88FE32F7-0B0B-4E3A-B53F-0AA9DFBDD402Q38987110-8BA2B298-D239-4D8B-930E-E0D84AEBE460Q39115000-C53466EF-21ED-4084-AF1A-22FB2304734EQ39140294-E9294131-0DCE-45C2-AE03-A33C4D052713Q39204459-FF7A68E2-45C3-474E-A694-668A4F8EB90EQ39236906-91B9E169-ACE2-4947-B9DE-CCCE06122B31Q39350860-2C2AD8F6-A515-4009-9136-A6605D772EB6Q47348380-81A68498-4967-4851-867F-5DA761F91755Q47367580-F55ED868-FDD3-483E-A916-FA5CC2FF4851Q47386188-AF96E1DA-52E4-4745-9A1D-0D849E1314B3Q47429828-2C5426D9-1852-4746-B85C-D59FE0412CEFQ48231903-0AD5CB36-6BF5-4282-93F0-7F4C6B5747B6Q48277301-DB8A11A6-2509-474B-A0EE-5379C409F3AEQ48359540-1D09731C-EB08-46D1-A965-E8A8FB340E32Q50233425-56B6C6E5-2FCB-44E2-8BBD-1B71F3859C3EQ51246605-84B589A4-EBF5-4419-BE1C-42A3AF438E41Q51278208-B93F2D53-E52A-43EC-85D9-960A99C76AE8Q52343188-18AE287D-5D49-423C-AEC2-C38070E9C9CEQ52595142-EE12966D-461E-4789-8B22-3BE6C46E8BACQ55399743-54F5BFF6-8474-46CE-9E25-00490B9D8A40
P2860
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
One-year efficacy and safety o ...... ension to a 26-week main trial
@ast
One-year efficacy and safety o ...... ension to a 26-week main trial
@en
type
label
One-year efficacy and safety o ...... ension to a 26-week main trial
@ast
One-year efficacy and safety o ...... ension to a 26-week main trial
@en
prefLabel
One-year efficacy and safety o ...... ension to a 26-week main trial
@ast
One-year efficacy and safety o ...... ension to a 26-week main trial
@en
P2093
P2860
P356
P1476
One-year efficacy and safety o ...... ension to a 26-week main trial
@en
P2093
H W Rodbard
P D Reiter
S C L Gough
P2860
P304
P356
10.1111/DOM.12498
P50
P577
2015-07-01T00:00:00Z